scholarly journals Is there room for further innovation in inhaled therapy for airways disease?

Breathe ◽  
2018 ◽  
Vol 14 (3) ◽  
pp. 216-224 ◽  
Author(s):  
Martyn F. Biddiscombe ◽  
Omar S. Usmani

Inhaled medication is the cornerstone in the treatment of patients across a spectrum of respiratory diseases including asthma and chronic obstructive pulmonary disease. The benefits of inhaled therapy have long been recognised but the most important innovations have occurred over the past 60 years, beginning with the invention of the pressurised metered dose inhaler. However, despite over 230 different device and drug combinations currently being available, disease control is far from perfect.Here we look at how innovation in inhaler design may improve treatments for respiratory diseases and how new formulations may lead to treatments for diseases beyond the lungs. We look at the three main areas where innovation in inhaled therapy is most likely to occur: 1) device engineering and design; 2) chemistry and formulations; and 3) digital technology associated with inhalers. Inhaler design has improved significantly but considerable challenges still remain in order to continually innovate and improve targeted drug delivery to the lungs. Healthcare professionals want see innovations that motivate their patients to achieve their goal of improving their health, through better adherence to treatment. Patients want devices that are easy to use and to see that their efforts are rewarded by improvements in their condition.Key pointsThe dictionary definition of innovation is the introduction of new things, ideas or ways of doing something. We show how this definition can be applied to inhaled therapy.We take a look at the past to see what drove innovation in inhaler design and how this has led to the current devices.We look at the current drivers of innovation in engineering, chemistry and digital technology and predict how this may translate to new devices.Can innovation help the healthcare professional manage their patients better?What does the patient expect from innovation in their device?Educational aimsTo understand the importance of inhaled medication in the treatment of lung diseases.To understand how innovation has helped advance some of the devices patients use today from basic and inefficient designs.To understand the obstacles that prevent patients from receiving optimal treatment from their inhalers.To understand how innovation in inhaler design can lead to improved treatment for patients and widen the range of diseases that can be treated via the inhaled route.

Author(s):  
Brent Utter

The global prevalence of asthma and chronic obstructive pulmonary disease (COPD) is on the order of hundreds of millions of individuals. The most common treatment approach is to take a self-administered inhaled medication. This study focuses on pressurized metered-dose inhalers (MDIs) where, unfortunately, rates of mishandling and misuse are extremely high and lead to improper treatment. One significant challenge results from the timing miscoordination of the medicine dispersion and inhalation breath. To address this, this study demonstrates the feasibility of automating the timing of the medicine dispersion by integrating a shape memory alloy (SMA) actuator and a differential pressure sensor into the casing of a traditional MDI. The approach is to measure the vacuum pressure created by an inspiratory breath, evaluate criteria indicating an acceptable breath, and if those criteria are met, heat the SMA actuator to depress the cartridge and disperse medicine. To meet actuation requirements and reliably depress the inhaler cartridge, two concepts for configuring an SMA wire were designed and compared with respect to complexity, actuation timing, and energy consumption. The proposed concept was able to disperse medicine in 263 ms, averaged over 100 actuations on a single battery charge, facilitating the early dispersion of medicine during an inhalation breath. By describing the design process of an SMA-actuated MDI that does not result in a significant increase of its weight or size, this study provides a practical technological approach for reducing the improper treatment of asthma and COPD due to timing miscoordination.


Author(s):  
H.Jaasminerjiit Kaur ◽  
Shashidharan Menon ◽  
Krupavaram B ◽  
A/P Subramaniama Kogila ◽  
V.Nagaraju G

A woman with aged 82 years old admitted to emergency hospital due to shortness of breath and chesty cough since last 3 days with underlying hypertension and chronic obstructive pulmonary disease. Patient’s physical examination revealed tachypnea with respiratory rate of 28 beats per minute and series of spirometry examination was performed to diagnosed with acute exacerbation of COPD (GOLD A). Medication such as SABA and SAAC metered-dose inhaler, corticosteroid, and intravenous potassium and sodium infusion were given to control the patient’s COPD condition as well as electrolyte imbalance issue. Follow up sessions and smoking cessation program also been arranged to improve and monitor the medical condition of the patient and to improve patient’s quality of life. Pharmacist intervention on counselling and education in inhaler spacer together with the MDI device with proper storage and cleaning direction should be given to the patient and care givers.


Dose-Response ◽  
2020 ◽  
Vol 18 (2) ◽  
pp. 155932582091783 ◽  
Author(s):  
Wijdan H. Ramadan ◽  
Aline Sarkis ◽  
Sandrine Sarine Aderian ◽  
Aline Milane

Objectives: Asthma and chronic obstructive pulmonary disease (COPD) are chronic illnesses of the airways affecting a good number of people in Lebanon and the Middle East. Pressurized metered-dose inhalers (pMDIs) are important drug delivery systems used to treat such pulmonary diseases. Drugs proven to be valuable and effective may fail to act effectively if such inhalers are used incorrectly. The purpose of this study was to assess the technical use of pMDIs by patients with pulmonary diseases presenting to the community pharmacies in Lebanon. Methods: A structured questionnaire was developed to collect data. A total of 601 patients using drugs delivered through pMDIs and presenting to 12 Lebanese community pharmacies were recruited to participate in the research project. The questionnaire items were divided into 3 subscales: subscale 1—assessing the device preparation; subscale 2—investigating the device use; and subscale 3—examining the knowledge and use of spacers. After confirming the reliability and validity of the survey tool, patients’ responses were analyzed and compared according to many variables. Results: Many patients answered inaccurately to questions assessing both the device preparation and use. Around 40% of patients said they do not coordinate the inhalation with pressing the canister down. The mean scores were 1.72 (± 0.73) over 6 and 5.67 (± 1.44) over 7 for subscales 1 and 2, respectively. The mean total score on all questions was 7.39 over 13, with a standard deviation of 1.75. While patients’ age did not impact the results, asthmatic, well-educated, male patients had fewer wrong answers when it comes to preparing and using the device ( P < .01). Conclusions: Our study showed that many patients with asthma and COPD might not be properly using their pMDIs. Appropriate inhaler use is crucial for successful pulmonary disease management. As pMDIs are one of the most difficult devices to use, proper and tailored instructions should be given to patients.


Sign in / Sign up

Export Citation Format

Share Document